NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

Natural killer cell adoptive therapy is a novel immunotherapy strategy for the treatment of multiple refractory tumors, including ovarian cancer. However, natural killer cells’ anti-tumor ...

SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's ...

Emerging intracellular checkpoint molecules offer new targets for improving NK cell antitumor activity, and understanding their mechanisms of action is crucial for identifying targetable checkpoints.

Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies Date: May 3, 2024 Source: German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) Summary ...

To date, NK-cell therapies have not seen the same success in solid tumors as in hematologic malignancies. This is believed to be because of the immunosuppressive tumor microenvironment that hampers NK ...

Review synthesizes research on NK cells' role in cancer immunity and their potential in therapeutics through bioengineering, immune checkpoint inhibitors, and cell engagers, highlighting ongoing ...

A collaboration between the University of Helsinki and the Dana-Farber Cancer Institute, Harvard Medical School, sheds light on the mechanisms how cancer cells evade killing by the immune system ...

This study revealed the key mechanism of NK cells dysfunction and immune evasion from the perspective of membrane topology, providing a new strategy for NK cell-based tumor immunotherapy.